The Delta variant and the change of strategy on the public health chessboard
DOI:
https://doi.org/10.24265/horizmed.2021.v21n3.01Abstract
During the last few weeks, Peru has been a spectator of what has been happening in certain European countries and in the United States of America, where there has been a dramatic increase in COVID-19 cases and hospitalizations, mostly due to the delta variant of SARS CoV-2. The increase in severe clinical forms and hospitalizations has led to increased vaccination and greater interest in the process, particularly in cities with low immunization rates. Still, the United States lags behind the European Union in inoculations and many of its citizens remain reluctant to receive the vaccine.
Downloads
References
Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(34): 1150-5.
Pagliusi S, Jarrett S, Hayman B, Kreysa U, Prasad SD, Reers M, et al. Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply. Vaccine. 2020; 38(34): 5418-23.
Wise J. Covid-19: Delta variant doubles risk of hospital admission compared with alpha variant, study shows. BMJ. 2021; 374: n2152.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
